News
Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy
The 51-year-old patient who died had suffered from limb-girdle muscular dystrophy, a group of genetic disorders that cause muscles to weaken and atrophy. Sarepta said Friday that the death occurred in a Phase 1 clinical trial for an investigational gene therapy called SRP-9004,
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Sarepta Therapeutics shares plunge over 37% as FDA weighs halting shipments of its key gene therapy, Elevidys, after patient ...
Sarepta Therapeutics (NASDAQ: SRPT) stock fell 42% Wednesday following news of a second fatal acute liver failure case linked to its Duchenne muscular dystrophy treatment Elevidys. The sharp ...
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Sarepta Therapeutics?
See Also: Why C3 AI Stock Is Moving Higher Monday Analyst Changes: Needham analyst Gil Blum maintained Sarepta with a Buy and raised the price target from $160 to $185.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback